Covid, Zingaretti: "Agreement with the Spallanzani Institute to test the Sputnik vaccine"
Breton: "The EU will not need the Sputnik vaccine"
Agreement between Moscow and Virchow for the production of Sputnik V in India: about 200 million doses per year
Share
March 23, 2021 "We are about to sign a memorandum of understanding with the Gamaleya center in Moscow, which developed the Sputnik V, for an exchange of biological material and researchers. I am very proud because this is a first in Europe: science is neutral, it must be far from geopolitical interests. We and Gamaleya have put at the center the need to have vaccines that work. We have found in the Gamaleya colleagues a great willingness to collaborate and to transparency ".
This was stated by Francesco Vaia, health director of the Lazzaro Spallanzani Institute in Rome, speaking at the Italian-Russian dialogue forum on 'Evolution of the pandemic, focus on the Russian Sputnik V vaccine, its characteristics and prospects for use'.
"The exchange of biological materials with the Russian institute in the light of the variants, which colleagues have undertaken to bring to Spallanzani, will allow us to identify the effectiveness of the antibodies produced after the vaccine - explains Vaia, entering into the merits of the details of the memorandum. This clinical study, in which I hope Professor Massimo Galli and the scholars of San Marino will also participate, for now will cover only 100 doses. But it will be an experiment that opens up to the possibility of verifying even a second vaccine administration, to followed by a first experimental inoculation with other products that did not give desired results. The in-depth study with Sputnik will therefore be decisive. For this reason - Vaia reiterates - we are even more pleased and proud because science can overcome any political and we will not be, as scientists, substitutes for politics under any circumstances. As early as April we will be able to provide the first data of the experiment.
mentation ".